[Antitumor effects of organic silicone compounds (IV). Antitumor effects of SDK-50 and SDK-47].
From the results of the 1st and 2nd screening as to the antitumor effect of organosilica compounds, two compounds, namely, SDK-50 (2-piperidinoethyl-phenyldimethyl-silane) and SDK-47 (3-N-2-propenylamino) propyltrimethyl-silane were selected. These two compounds were further tested by using the solid form cancer of Ehrlich, sarcoma-180 and Lewis lung carcinoma in mice and moreover the rats bearing ascites hepatomas. AH-13, 130, 272, 44, 66F, 66, 7974, 41-C, 60-C and 109A. From the summarized data, it may be said that the effect of SDK-50 is relatively superior to SDK-47. In addition of the inhibitory effect on cancer cells, it was found that SDK-50 possesses an activating effect of delayed type hypersensitivity. This effect of SDK-50 was equivalent to PSK or SPG.
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D005260:Female; D006968:Hypersensitivity, Delayed / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008813:Mice, Inbred ICR; D008815:Mice, Inbred Strains; D051381:Rats; D012513:Sarcoma, Experimental / Q000188:drug therapy; D012828:Silicones / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D012828:Silicones; C038339:SDK 50; C038338:SDK 47